Sandoz and mAbxience Sign Global Agreement to Develop and Sell an Emicizumab Biosimilar for Hemophilia A
mAbxience, majority-owned by Fresenius with partial ownership by Insud Pharma, and Sandoz announced on Friday, September 18, 2026 a licensing, development, manufacturing, and commercialization agreement for a biosimilar candidate of emicizumab for hemophilia A. mAbxience will develop and manufacture the product at its GMP-approved facilities in Spain and Argentina, and Sandoz will hold exclusive global commercialization rights outside Argentina, Uruguay, and Paraguay. The companies estimate the global reference market at about $5.7 billion. Financial terms were not disclosed.